Patent US4420481A successfully refreshed from Google Patents.
US4420481A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of piperazine compounds as immunopotentiating agents
Assignee: Mitsui Toatsu Chemicals Inc
•
Filing: 1981-02-19
•
Granted: 1983-12-13
•
Expires: 2001-02-19
Abstract
Abstract The present invention relates to a novel piperazine compound represented by the following general formula (I): <IMAGE> (I) wherein R stands for an alkyl or phenyl group, and n is a number of 4 or 5. These compounds are valuable as an immunopotentiators, such as for the treatment of chronic rheumatoid arthritis and other diseases accompanied by reduction or abnormal change of immune function.
Inventors
- 👤 Yutaka Okazaki
- 👤 Hiroshi Tokuda
- 👤 Shiyoichiro Miyahara
- 👤 Yoshitsugu Yamada
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 03:16
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/16; C07D295/20; C07D295/215; A; A61; A61P; A61P37/00; A61P37/02; A61P37/04
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
64 words
A method for the treatment of chronic rheumatoid arthritis, comprising administering, to a patient having chronic rheumatoid arthritis, an immunopotentiating amount of a piperazine compound represented by the following formula (I): ##STR22## wherein R is a C 1-4 alkyl group or a phenyl group and n is 4 or 5, in the form of a free base or a biologically acceptable acid addition salt.
Claim 2
Independent Claim
64 words
A method for the treatment of chronic rheumatoid arthritis, comprising administering, to a patient having chronic rheumatoid arthritis, an immunopotentiating amount of a piperazine compound represented by the following formula (I): ##STR22## wherein R is a C 1-4 alkyl group or a phenyl group and n is 4 or 5, in the form of a free base or a biologically acceptable acid addition salt.
Claim 3
Independent Claim
57 words
A method for activating cellular immunity response in vivo comprising administering an immunopotentiating amount of a piperazine compound represented by the following formula (I): ##STR23## wherein R is a C 1-4 alkyl group or a phenyl group and n is 4 or 5, in the form of a free base or a biologically acceptable acid addition salt.
Claim 4
Independent Claim
57 words
A method for activating cellular immunity response in vivo comprising administering an immunopotentiating amount of a piperazine compound represented by the following formula (I): ##STR23## wherein R is a C 1-4 alkyl group or a phenyl group and n is 4 or 5, in the form of a free base or a biologically acceptable acid addition salt.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-12-12 | 1987-06-13 | 1987-12-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-12-12 | 1991-06-13 | 1991-12-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-12-12 | 1995-06-13 | 1995-12-13 | $7700.00 | Window Closed / Lapsed |